SYSTEMATIC REVIEW article
Front. Endocrinol.
Sec. Clinical Diabetes
Clinical Effect of Intravitreal Ranibizumab and Laser Photocoagulation on Diabetic Macular Oedema: A Meta-analysis
Provisionally accepted
- Hebei Provincial People's Hospital, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To systematically evaluate the clinical effect of intravitreal ranibizumab (IVR) and laser photocoagulation on diabetic macular oedema (DME). Method: A systematic search was conducted of five English databases from the establishment of each database to 31 January 2024, and a meta-analysis was performed using Review Manager 5.3 software. Result: A total of 1,040 patients were included across 10 articles, where 531 patients had been treated with IVR and 509 with laser photocoagulation. The results of the meta-analysis showed that visual acuity improvement in the IVR group was better than in the laser photocoagulation group. The difference was statistically significant (best corrected visual acuity [BCVA], Mean Difference (MD) = 5.69, 95% confidence interval [CI]: 4.51, 6.86, P < 0.001). There was no significant difference in BCVA based on Logarithm of the Minimum Angle of Resolution (logMAR) value (MD = −0.07, 95%CI: −0.15, −0.01, P = 0.07). The improvement of macular oedema in IVR was better than in the laser photocoagulation group (central macular thickness, MD = −30.93, 95% CI: −35.18, −26.68, P < 0.001). There were more adverse reaction events in the IVR group than in the laser photocoagulation group, and the difference was statistically significant (odds ratio = 8.82, 95% CI: 3.06, 25.43, P < 0.001). Conclusion: Intravitreal ranibizumab remains superior to laser photocoagulation in improving vision and reducing macular oedema in DME, albeit with higher adverse events. These findings support IVR's continued relevance in contemporary practice, particularly where newer anti-vascular endothelial growth factor agents are unavailable.
Keywords: intravitrealranibizumab, Laserphotocoagulation, diabeticmacularoedema, Acuity, Meta-analysis
Received: 24 Apr 2025; Accepted: 03 Nov 2025.
Copyright: © 2025 Hu, Li, Ma and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Jianmin Wang, wwangjianmin9@126.com
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.